Current Report Filing (8-k)
June 25 2021 - 4:31PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): June 22, 2021
ADVAXIS,
INC.
|
(Exact
name of registrant as specified in its charter)
|
Delaware
|
|
001-36138
|
|
02-0563870
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
9
Deer Park Drive, Suite K-1
Monmouth
Junction, NJ
|
|
08852
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (609) 452-9813
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
stock, par value $0.001 per share
|
|
ADXS
|
|
Nasdaq
Capital Market
|
Preferred
Stock Purchase Rights
|
|
-
|
|
Nasdaq
Capital Market
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
3.01
|
Notice
of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
|
As
previously disclosed in its Current Reports on Form 8-K filed on April 10, 2020, April 20, 2020, and December 22, 2020, Advaxis, Inc.
(the “Company”) received written notice from the staff of the Listing Qualifications Department of The Nasdaq Stock Market
LLC (“Nasdaq”) indicating that the Company was not in compliance with the minimum $1.00 bid price requirement for continued
listing set forth in Nasdaq Listing Rule 5550(a)(2) (the “Listing Rule”). Following the Company’s transfer from The
Nasdaq Global Market to The Nasdaq Capital Market on December 24, 2020, the Company was afforded until June 21, 2021, to regain compliance
with the Listing Rule.
On
June 22, 2021, the Company received notification from Nasdaq that the Company had not regained compliance with the Listing Rule.
The notification indicated that the Company’s common stock would be subject to delisting unless the Company timely requests
a hearing before a Nasdaq Hearing Panel (the “Panel”). Accordingly, the Company intends to timely request a hearing
before the Panel. The hearing request will stay any suspension or delisting action pending the hearing and the expiration of any
additional extension period granted by the Panel following the hearing. In that regard, the listing rules permit the Panel to
grant a further extension, which will not extend beyond December 20, 2021.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
June
25, 2021
|
ADVAXIS,
INC.
|
|
|
|
|
By:
|
/s/
Kenneth A. Berlin
|
|
Name:
|
Kenneth
A. Berlin
|
|
Title:
|
President
and Chief Executive Officer, Interim Chief Financial Officer
|
Ayala Pharmaceuticals (CE) (USOTC:ADXS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ayala Pharmaceuticals (CE) (USOTC:ADXS)
Historical Stock Chart
From Sep 2023 to Sep 2024